Medical/Pharmaceuticals
OBiO has launched its state-of-the-art GMP production facility Intelli-M to expedite innovative and advanced therapies to patients who are in need.
SHANGHAI, Sept. 27, 2023 /PRNewswire/ -- In Shanghai, China, on August, OBiO Technology, a prominent leader in the Cell and Gene Therapy (CGT) field and a Contract Development and Manufacturing Organization, proudly unveiled the official launch of its state-of-the-art GMP production facility, chr...
2023-09-27 21:00
2453
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference
These are the first in a series of presentations scheduled through the end of the year sharing advances to SK Biopharmaceutical's targeted protein degradation (TPD) pipeline SEOUL, South Korea and KING OF PRUSSIA, Pa., Sept. 26, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech focuse...
2023-09-27 08:30
2537
ABM Therapeutics' ABM-1310 Granted Fast Track Designation by the FDA Following Orphan Drug Designation
SAN DIEGO and SHANGHAI, Sept. 26, 2023 /PRNewswire/ -- ABM Therapeutics is pleased to announce today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the investigation of ABM-1310 for the treatment of Glioblastoma (GBM) patients carrying BRAF V600E mutation,...
2023-09-27 00:00
2944
China Jo-Jo Drugstores Announces $2.59 Million Registered Direct Offering
HANGZHOU, China, Sept. 26, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ...
2023-09-26 21:00
4288
Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update
Highlights Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design and trial endpoints. UK sites added to the XanaCIDD trial of cognitive impairment associated with depression, due to report resu...
2023-09-26 20:51
2623
WuXi Vaccines Launches Its First Vaccines CDMO Site in China
SUZHOU, China, Sept. 26, 2023 /PRNewswire/ -- WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou,China. The opening will add drug substanc...
2023-09-26 15:41
2929
Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch
* Chime Biologics has entered into a strategic collaboration with Kings Pharm for a biosimilar asset, providing cell line development, process development, global GMP manufacturing, commercialization and regulatory filing support. Chime will also supply the commercial production once the produc...
2023-09-25 20:15
2368
Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology
SINGAPORE, Sept. 25, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited
2023-09-25 19:00
2253
MediLink Therapeutics: Focuses on ADC research and development to promote new prospects for cancer treatment
----- YL201 Phase I/II Investigators Meeting was successfully held in Guangzhou, China GUANGZHOU, China, Sept. 23, 2023 /PRNewswire/ -- On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered inGuangzhou to participate in the YL201 P...
2023-09-23 18:29
3381
Concord Medical Reports Financial Results for the First Half of 2023
BEIJING, Sept. 22, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extens...
2023-09-23 05:00
6607
Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development
* Chime Biologics and Panolos Bioscience have entered into a global strategic collaboration agreement on a novel multi-specific protein drug. Chime Biologics will provide development and manufacturing services to Panolos Bioscience for PB203, a next-generation immuno-oncology drug. WUHAN, China...
2023-09-22 20:15
2645
MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil
FOSTER CITY, Calif., Sept. 22, 2023 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has g...
2023-09-22 16:41
2446
FDA Grants Fast Track Designation to 9MW3011
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that FDA has granted Fast Track Designation (FTD) to 9MW3011 (R&D code in the US: MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (P...
2023-09-22 08:00
2388
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function
SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced its partnership with Aditum Bio to create Celexor Bio (Celexor), a ne...
2023-09-21 21:00
5323
Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Dizal announced today that the China National Medical Products Administration (NMPA) has granted priority review status to golidocitinib, Dizal's investigational JAK1-only inhibitor, for the treatment of relapsed or refractory peripheral T-cell lymphoma (r...
2023-09-21 20:26
2392
AVANCE CLINICAL APPOINTS US-BASED EXECUTIVES - SVP SCIENTIFIC AND REGULATORY AFFAIRS, AND DIRECTOR BUSINESS DEVELOPMENT
ADELAIDE, Australia and RALEIGH, N.C., Sept. 21, 2023 /PRNewswire/ -- Avance
Clinical, the award-winning Australian and North American market-leading CRO
for biotechs, announces two key appointments in the US to support its continued
global growth.
2023-09-21 19:30
2529
Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncology
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of the treatment of metastatic pancreat...
2023-09-21 16:00
2253
Hepagene Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for HPG7233 THR Beta Agonist
HONG KONG and NANJING, China, Sept. 20, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc. a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its HPG7233, an agonist of Thyroid H...
2023-09-20 22:00
1962
Taiwan's Premier Health Brand Unveils Best Quality Pineapple Enzyme for Digestive Health
NISORO HEALTH introduces high-quality Pineapple Enzyme, a digestive elixir blendingTaiwan's pineapples and LJ88 probiotics. It enhances digestion, promotes gut health, and is suitable for all ages. TAIPEI, Sept. 20, 2023 /PRNewswire/ -- Taiwan is renowned for its exceptional products, and NISORO...
2023-09-20 21:00
2467
Double Honors: Sanyou Bio Earns "Most Trusted Biopharmaceutical CXO Partner" and "Most Influential Partner of the Year" Awards
SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- Sanyou Bio's consecutive wins reflect our clients' trust, and our proven track record, raising expectations for our future. This recognition from peers and industry experts motivate us to remain committed to our mission, and to consistently provide high-qu...
2023-09-20 20:00
1799
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 291 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
8629
QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration
2026-09-12 09:00
7947
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
7041
